Given the limitations of sample sizes and individual variability, these findings warrant careful interpretation [8]
Fellow pharma powerhouse Roche has also jumped into the oral obesity arena with the $2.7 billion acquisition of Carmot Therapeutics in December 2023, giving it access to CT-388 and CT-868, both of which are dual agonists of the GLP-1 and GIP receptors with best-in-class potential for obesity, Roche said at the time
But is it safe to go that route
They can do a simple ultrasound scan to check what is really going on
Falling estrogen levels often cause weight gain around the belly, insulin resistance, and higher cholesterol , increasing the risk for diabetes and heart disease
JC: Writing review & editing, Writing original draft, Supervision, Investigation, Formal analysis, Data curation